Hyperlipidemias: Clinical Trials

388 trials for Hyperlipidemias, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

388 completed. 388 Phase 3, 30 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 3388Completed 388
Phase 230Completed 30

Follow Hyperlipidemias: new trials by email Literature Review of Hyperlipidemias trials Research Report on Hyperlipidemias

Trials (filtered) newest first · largest first

All 388 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
IBI306 Monotherapy in Non-Familial Hypercholesterolemia and Mixed Hyperlipidemia
IBI306, placebo - Non-Familial Hypercholesterolemia and Mixed Hyperlipidemia
Phase 3CompletedInnovent Biologics (Suzhou) Co. Ltd.1982026-04-012026-11-17
A Clinical Study of Enlicitide in Participants With High Cholesterol (MK-0616-037)
Enlicitide, Rosuvastatin, Placebo for Enlicitide - Hyperlipidemia
Phase 3CompletedMerck Sharp & Dohme LLC9962025-11-112026-11-17
A Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Clinical Study Evaluating the Efficacy and Safety of SHR-1918 in Patients With Homozygous Familial Hypercholesterolemia
SHR-1918, SHR-1918 placebo - Homozygous Familial Hypercholesterolemia
Phase 3CompletedBeijing Suncadia Pharmaceuticals Co., Ltd552025-02-132025-12-15
A Clinical Study to Evaluate the Efficacy, Tolerability, and Safety of Bempedoic Acid
Bempedoic Acid Tablet, Placebo - Primary Hyperlipidemia
Phase 3CompletedGan & Lee Pharmaceuticals.2452024-12-202026-11-13
A Study of the Safety of Mibavademab in Pediatric and Adult Participants Switching From Metreleptin to Mibavademab for the Treatment of Generalized Lipodystrophy (GLD)
mibavademab - Generalized Lipodystrophy
Phase 3CompletedRegeneron Pharmaceuticals92024-12-162026-07-29
A Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of AG2304T and AG2304R
AG2304T, AG2304R - Hypercholesterolemia
Phase 3CompletedAhn-Gook Pharmaceuticals Co.,Ltd1582024-09-302026-06-18
Study of Plozasiran in Adults With Severe Hypertriglyceridemia
Plozasiran Injection, Placebo - Severe Hypertriglyceridemia
Phase 3CompletedArrowhead Pharmaceuticals3112024-07-232026-10-09
Study of Plozasiran (ARO-APOC3) in Adults With Severe Hypertriglyceridemia
Plozasiran Injection, Placebo - Severe Hypertriglyceridemia
Phase 3CompletedArrowhead Pharmaceuticals4462024-07-222026-10-08
A Study to Evaluate the Efficacy and Safety of Enlicitide (MK-0616, Oral PCSK9 Inhibitor) Compared With Ezetimibe or Bempedoic Acid or Ezetimibe and Bempedoic Acid in Adults With Hypercholesterolemia (MK-0616-018/CORALreef AddOn)
Enlicitide, Ezetimibe, Bempedoic Acid - Hypercholesterolemia
Phase 3CompletedMerck Sharp & Dohme LLC3012024-07-082026-03-27
Phase 3 Study of Plozasiran in Adults With Hypertriglyceridemia
Plozasiran Injection, Placebo - Hypertriglyceridemia
Phase 3CompletedArrowhead Pharmaceuticals14562024-05-212026-09-25
Study of Obicetrapib & Ezetimibe Fixed Dose Combination on Top of Maximum Tolerated Lipid-Modifying Therapies
Combination Therapy, Monotherapy obicetrapib, Monotherapy ezetimibe - Dyslipidemias, Hypercholesterolemia
Phase 3CompletedNewAmsterdam Pharma4072024-03-012025-10-08
A Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Clinical Study to Evaluate the Safety and Efficacy of SAL003 in Combination With Statin Therapy in Patients With Hypercholesterolemia and Mixed Dyslipidemia
SAL003 140 mg, Placebo - Hyperlipidemias, Hypercholesterolemia, Mixed Dyslipidemia
Phase 3CompletedShenzhen Salubris Pharmaceuticals Co., Ltd.7202023-12-192025-11-28
A Study of SAL003 in Participants With Hypercholesterolemia and Mixed Dyslipidemia
SAL003 140 mg, Placebo - Hyperlipidemias
Phase 3CompletedShenzhen Salubris Pharmaceuticals Co., Ltd.6182023-10-232025-12-19
A Study of Enlicitide Decanoate (MK-0616 Oral PCSK9 Inhibitor) in Adults With Hypercholesterolemia (MK-0616-013) CORALreef Lipids
Enlicitide Decanoate, Placebo - Hypercholesterolemia, Familial Hypercholesterolemia
Phase 3CompletedMerck Sharp & Dohme LLC29122023-08-102026-09-24
A Study of Enlicitide Decanoate (MK-0616 Oral PCSK9 Inhibitor) in Adults With Heterozygous Familial Hypercholesterolemia (MK-0616-017/CORALreef HeFH)
Enlicitide Decanoate, Placebo - Hypercholesterolemia, Familial Hypercholesterolemia
Phase 3CompletedMerck Sharp & Dohme LLC3032023-08-082026-02-24
Efficacy and Safety of Inclisiran as Monotherapy in Chinese Adults With Low or Moderate ASCVD Risk and Elevated Low-density Lipoprotein Cholesterol.
Inclisiran, Matching Placebo for Inclisiran - Primary Hypercholesterolemia or Mixed Dyslipidemia
Phase 3CompletedNovartis Pharmaceuticals2072023-07-112026-01-13
To Evaluate the Efficacy and Safety of Pegozafermin in Subjects With Severe Hypertriglyceridemia
Pegozafermin, Placebo - Severe Hypertriglyceridemia
Phase 3Completed89bio, Inc.3692023-06-152026-07-07
A Phase III Confirmatory Study of K-877 (Pemafibrate) in Patients With Hypercholesterolemia and Statin Intolerance
K-877 0.2 mg/day (once daily), K-877 0.4 mg/day (once daily), Placebo (once daily) - Hypercholesterolemia
Phase 3CompletedKowa Company, Ltd.712023-05-012025-12-11
Efficacy and Safety of Inclisiran as Monotherapy in Patients With Primary Hypercholesterolemia Not Receiving Lipid-lowering Therapy.
Inclisiran, Ezetimibe, Matching Placebo for Inclisiran - Hypercholesterolemia
Phase 3CompletedNovartis Pharmaceuticals3502023-03-152025-10-16
A Clinical Trial to Evaluate the Efficacy and Safety of Co-administration of DWC202206 and DWC202207 in Patients With Concomitant Hypertension and Hyperlipidemia
(D) DWC202206, (D) DWC202207, (P) DWC202206 - Hypertension, Hyperlipidemias
Phase 3CompletedDaewoong Pharmaceutical Co. LTD.2142023-02-232026-04-30

Showing 20 of 388. Sign in to see all of them.

Narrower conditions

Hypercholesterolemia (229)  ·  Dyslipidemias (48)  ·  Hypertriglyceridemia (46)  ·  Hyperlipoproteinemia Type II (39)  ·  Hypertension (35)  ·  Atherosclerosis (24)  ·  Coronary Disease (24)  ·  Homozygous Familial Hypercholesterolemia (23)  ·  Diabetes Mellitus (20)  ·  Cardiovascular Diseases (19)  ·  Diabetes Mellitus, Type 2 (16)  ·  Obesity (11)  ·  Heart Diseases (10)  ·  Hyperlipoproteinemias (8)

Broader conditions

Nutritional and Metabolic Diseases (388)  ·  Lipid Metabolism Disorders (383)  ·  Metabolic Diseases (381)  ·  Dyslipidemias (340)  ·  Vascular Diseases (78)  ·  Cardiovascular Diseases (69)  ·  Congenital, Hereditary, and Neonatal Diseases and Abnormalities (63)  ·  Metabolism, Inborn Errors (61)  ·  Lipid Metabolism, Inborn Errors (60)  ·  Genetic Diseases, Inborn (59)  ·  Hyperlipoproteinemias (59)  ·  Glucose Metabolism Disorders (38)  ·  Endocrine System Diseases (35)  ·  Arterial Occlusive Diseases (27)

Interventions

Ezetimibe (78)  ·  Atorvastatin (74)  ·  Rosuvastatin Calcium (53)  ·  Simvastatin (50)  ·  evolocumab (30)  ·  alirocumab (23)  ·  Fenofibrate (16)  ·  Ezetimibe, Simvastatin Drug Combination (11)  ·  Pravastatin (11)  ·  1-((1-(3-acetoxy-2,2-dimethylpropyl)-7-chloro-5-(2,3-dimethoxyphenyl)-2-oxo-1,2,3,5-tetrahydro-4,1-benzoxazepin-3-yl)acetyl)piperidine-4-acetic acid (9)  ·  torcetrapib (9)  ·  8-hydroxy-2,2,14,14-tetramethylpentadecanedioic acid (8)  ·  ALN-PCS (8)  ·  Omacor (8)  ·  pitavastatin (8)

Sponsors

Organon and Co (57)  ·  AstraZeneca (31)  ·  Amgen (26)  ·  Sanofi (18)  ·  Merck Sharp & Dohme LLC (16)  ·  Pfizer (14)  ·  Takeda (12)  ·  Regeneron Pharmaceuticals (9)  ·  Novartis Pharmaceuticals (8)  ·  Kowa Research Europe (7)  ·  Pfizer's Upjohn has merged with Mylan to form Viatris Inc. (7)  ·  Esperion Therapeutics, Inc. (6)  ·  Kastle Therapeutics, LLC (6)  ·  National Heart, Lung, and Blood Institute (NHLBI) (6)  ·  University Health Network, Toronto (5)

Countries

United States (153)  ·  Canada (99)  ·  Netherlands (63)  ·  Spain (57)  ·  South Africa (55)  ·  Germany (54)  ·  United Kingdom (51)  ·  France (49)  ·  Czechia (48)  ·  Italy (46)  ·  South Korea (42)  ·  Poland (41)  ·  Hungary (37)  ·  Belgium (36)  ·  Denmark (36)

Top investigators

Russell Esterline (8)  ·  Ron Haberman, MD (5)  ·  Dragos Budinski, Med Dr. (4)  ·  Dragos Budinski, MD (3)  ·  Evan A Stein, MD PhD (3)

Results publications

PMID 33078867, PMID 27777279, PMID 30183102, PMID 34298554, PMID 21518985, PMID 28304227, PMID 25614280, PMID 27578134, PMID 28964736, PMID 32609313, PMID 35916348, PMID 37994400, PMID 28391886, PMID 29685591, PMID 33990512, PMID 35277540, PMID 37658997, PMID 38063346, PMID 38757725, PMID 41604274, PMID 21401833, PMID 22087637, PMID 22500948, PMID 23325450, PMID 24014831, PMID 25269777, PMID 25431239, PMID 25893544, PMID 27206952, PMID 27418543, PMID 27596132, PMID 27939227, PMID 32187462, PMID 34989797, PMID 36520008, PMID 37282500, PMID 37565307, PMID 40064331, PMID 40587053, PMID 41211918, PMID 41903707, PMID 12034651, PMID 12719279, PMID 15311720, PMID 15389231, PMID 15486569, PMID 15536230, PMID 16218799, PMID 16651474, PMID 17325296

NIH funding

2015 (10), 2005 (7), 2017 (7), 2014 (5), 2023 (5), 2008 (2), 2016 (2), 2004 (1), 2018 (1), 2019 (1), N01HC95178 (1), N01HC95179 (1), N01HC95180 (1), N01HC95181 (1), N01HC95182 (1)